TABLE 3.
Variables | Placebo | Eriomin® | ||
---|---|---|---|---|
0 week | 12°week | 0 week | 12°week | |
Biometric | ||||
Systolic BP, mmHg | 125 ± 10 | 124 ± 11 | 102 ± 25 | 102 ± 26 |
Diastolic BP, mmHg | 78.0 ± 7.9 | 74.0 ± 7.7 | 79.0 ± 9.4 | 77.0 ± 9.5 |
Body weight, kg | 103 ± 17 | 104 ± 17 | 102 ± 25 | 102 ± 26 |
BMI, kg/m2 | 34.5 ± 6.5 | 34.5 ± 6.7 | 34.5 ± 7.1 | 34.5 ± 7.3 |
Lean mass, kg | 34.5 ± 7.3 | 34.7 ± 7.4 | 34.9 ± 6.7 | 34.9 ± 7.3 |
Fat mass, kg | 37.7 ± 8.9 | 38.3 ± 15.6 | 40.1 ± 17.8 | 39.3 ± 18.6 |
Waist/Hip | 1.05 ± 0.10 | 1.05 ± 0.09 | 1.06 ± 0.08 | 1.06 ± 0.09 |
Nutritional | ||||
Energy, kcal/day | 3538 ± 932 | 3500 ± 927 | 3180 ± 855 | 3249 ± 1006 |
(TEE, kcal/day) | (2453 ± 320) | (2383 ± 392) | (2318 ± 356) | (2419 ± 306) |
Carbohydrates, g/day | 380 ± 82 | 415 ± 126 | 374 ± 119 | 360 ± 98 |
(AMDR = 45–65%TEE) | (44 ± 8%) | (48 ± 10%) | (47 ± 6%) | (46 ± 9%) |
Protein, g/day | 143 ± 52 | 138 ± 46 | 135 ± 45 | 135 ± 45 |
(AMDR = 10–35%TEE) | (16 ± 3%) | (16 ± 4%) | (17 ± 3%) | (17 ± 5%) |
Lipids | 162 ± 66 | 145 ± 38 | 129 ± 35 | 142 ± 76 |
(AMDR = 20–35% TEE) | (40 ± 8%) | (38 ± 11%) | (36 ± 6%) | (42 ± 25%) |
Saturated Fat Acids | 37 ± 16 | 49 ± 12 | 40 ± 10 | 44 ± 20 |
(AHA ≤7% TEE) | (13 ± 3%) | (13 ± 4%) | (11 ± 2%) | (13 ± 7%) |
Fibers, g/day | 17.8 ± 3.3 | 19.5 ± 3.9 | 19.6 ± 3.0 | 19.4 ± 3.8 |
(AI = 25 g/day) | Below | Below | Below | Below |
Cholesterol, mg/day | 566 ± 188 | 554 ± 117 | 553 ± 156 | 504 ± 118 |
(AHA ≤ 200 mg/day) | Above | Above | Above | Above |
Note: Data presented as mean ± SD. The values in (italic) represent % of macronutrient energy (kcal/day) regarding the Total Energy Expenditure (TEE). No statistic differences detected intragroup (week 0 vs. 12) or intergroups (Eriomin vs. Placebo) (p ≥ .05).
Abbreviations: AHA, American Heart Association; AI, Adequate Intake; AMDR, acceptable macronutrient distribution ranges; TEE, total energy expenditure (kcal/day).